2 stocks I am following: CYPH - they own a technology to make TAXOL that would cut the current cost by 75%. TAXOL now is marketed by BMY BCHE - mentioned in recent BW. they own lamuvidine, an antiviral agent with broad implications for HIV, Hep-B, etc. Glaxo is negotiating a marketing deal in China, where Hep-B is a epidemic.
PFE will be in the low 60's/high 50's and will rebound when viagra is approved mid-year.